FierceBiotech Names Orchard Therapeutics Limited as One of Its “Fierce 15” Biotech Companies of 2016

Orchard logo

London, UK, September 21, 2016 / B3C newswire / -- Orchard Therapeutics Limited is proud to report that it has been named by FierceBiotech as one of 2016’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. The announcement was made during the FierceBiotech Drug Development Forum, which took place Monday September 19 in Boston, MA.

Orchard Therapeutics is a clinical-stage biotechnology company dedicated to bringing transformative ex-vivo gene therapies to patients with serious and life-threatening orphan diseases.

Orchard’s technology uses the potential of the ex-vivo autologous haematopoietic stem cell gene therapy to restore normal gene function in severe and life-threatening inherited disorders such as ADA-SCID (adenosine deaminase severe combined immunodeficiency) and MPS IIIA (mucopolysaccharidosis type IIIA).

“We are honoured to be recognized by FierceBiotech and to be included in such a promising group of Fierce companies,” said Alexander Pasteur, Orchard Therapeutics Interim CEO and Partner at F-Prime Capital. “Since the launch of Orchard earlier this year, we have made tremendous progress in advancing our pre-clinical and clinical programs. We have a lot of work in front of us to accomplish our mission, and we are really proud to receive such a level of recognition today.”


About FierceBiotech
FierceBiotech is the biotech industry's daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 160,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories.

The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. FierceBiotech is an internationally recognized daily report reaching a network of over 275,000 biotech and pharma industry professionals. It provides subscribers with authoritative analysis of the day's top stories.  Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position. The 2016 list of “Fierce 15” companies can be found online at http://www.fiercebiotech.com/special-report/fiercebiotech-s-2016-fierce-15.

About Orchard Therapeutics
Orchard Therapeutics is a clinical-stage biotechnology company dedicated to bringing transformative ex-vivo gene therapies to patients with serious and life-threatening orphan diseases.


Contact

Sylvie Blanchier
+44 2038 232 149

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
Ok